Berlin - Since the early benefit assessment was introduced in 2011, 256 medicinal products have been assessed in 367 decision-making procedures by the Federal Joint Committee (). This is shown by the response of the federal government to small question from the FDP parliamentary group in the Bundestag.
According to this, an additional benefit could be determined in 153 of 256 cases. The additional benefit fell into one of the categories “considerable”, “considerable”, “minor” or “not quantifiable”.
With the entry into force of the majority of the regulations of the Medicines Market Reform Act (AMNOG) on January 1, 2011, the G-BA will initiate benefit assessment for every medicinal product with new active ingredient immediately after its entry into the market.
Whether manufacturer can prove an additional benefit compared to the appropriate comparator therapy is decisive for the subsequent negotiation between the reimbursement amount the (GKV) and the pharmaceutical companies.